Innate Pharma, Inc.

Innate Pharma and IFLI announce $7.9M partnership to develop IPH6501 in follicular lymphoma, including $3M upfront and $4.9M in milestone-based investments. The collaboration expands the ongoing Phase 1/2 trial of IPH6501 to include relapsed/refractory follicular lymphoma patients.

The non-small cell lung cancer market is driven by increasing NSCLC cases, uptake of immune checkpoint inhibitors, emerging premium therapies, and awareness of mutations. DelveInsight's report covers current treatment practices, emerging drugs, market share, and forecasted market size from 2019 to 2032 in 7MM. Key companies and therapies include EMD Serono, Merck, AstraZeneca, Bristol-Myers Squibb, and therapies like M1774, C-TIL051, and Osimertinib. FDA approvals for Opdivo and Tagrisso in 2024 highlight advancements in treatment.

NK cell therapy, a promising cancer treatment, sees robust R&D with 140+ companies developing 160+ therapies. Key players include Amgen, Innate Pharma, Nektar Therapeutics, and others. Promising therapies like Bemarituzumab, Monalizumab, and NKTR-225 are in various clinical phases. Recent milestones include Immunitybio's CAR-NK cell therapy for NHL, Nkarta's NKX019 for AAV, and KGen Biotech's SNK01 advancing to Phase II.

Bullous pemphigoid (BP) affects elderly patients, often misdiagnosed, with no approved therapies in the US. Current treatments include off-label corticosteroids and immunomodulators. The BP pipeline includes advanced Phase III therapies like AstraZeneca’s Fasenra, Sanofi/Regeneron’s Dupixent, and Akari Therapeutics’ nomacopan. Unmet needs and market opportunities are significant due to lack of approved therapies and diagnostic biomarkers.

Innate Pharma SA will co-host a hybrid scientific symposium on October 3, 2024, with Mount Sinai, featuring key opinion leaders in immunotherapy. The event marks Innate Pharma's 25th anniversary and highlights next-generation immunotherapy discoveries.

Innate Pharma received FDA clearance for its IND application to start a Phase I trial of IPH4502, a topoisomerase I inhibitor ADC targeting Nectin-4 solid tumours. The open-label, multicentre trial will evaluate IPH4502's tolerability, safety, and initial efficacy in patients with advanced solid tumours expressing Nectin-4.

Innate Pharma announces FDA clearance of IND for IPH4502, a Nectin-4 ADC for solid tumors, initiating Phase 1 study.

FDA clears Innate Pharma's IND application for Phase 1 study of IPH4502, a novel Nectin-4 targeting ADC in solid tumors.